drugset / Trial / NCT00359788
A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.
Parallel-groupTreatment
Summary
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler (MDI) Chlorofluorocarbon Inhalation Aerosol 2 actuations four times a day in Chronic Obstructive Pulmonary Disease (COPD) patients currently prescribed Combivent® MDI.
Timeline
- Start
- 2006-07
- Primary completion
- 2008-04
- Completion
- —
Outcome
Met primary endpoint
registry analysis (superiority or other test); Tiotropium vs Combivent (Ipratropium/Albuterol); p <0.0001; Mean Difference (Final Values) 0.106 (95% CI 0.055 to 0.157); ANCOVA NCT00359788 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipratropium | Small molecule | — | Inhaled |
| Subject | Salbutamol | Unknown | — | Inhaled |
| Subject | Tiotropium | Other / unclassified | 18 ug | Inhaled |